Blood clotting product stability in ambulances under real conditions
Part of Blood & lymphatic, Injuries & trauma clinical trials.
This study checks if blood clotting products kept in emergency ambulances stay effective under normal, real-world storage conditions. It may help ensure these life-saving products work properly when needed most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an emergency ambulance service that stores Fibryga or Octaplas LG AB clotting products.
- The products must be kept in the ambulance under routine operational conditions.
- The products must be available for laboratory testing at scheduled times during the study.
- No damaged packaging or incomplete storage documentation.
- Products must not have been accidentally removed or exposed to unusual conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a standard set of emergency blood transfusions for people with life-threatening bleeding from a serious injury. It aims to improve survival by giving blood products quickly before reaching the hospital.
This trial checks if a fast bedside test for fibrinogen (a protein that helps blood clot) can help guide treatment for trauma patients who are actively bleeding. It may lead to better care in the emergency department.
This trial tests whether a newer, faster blood test (viscoelastic testing) can better guide treatment for bleeding after a severe injury compared to standard blood tests. If you are in the emergency room shortly after a serious trauma, this study may help doctors decide the right treatments to stop bleeding more quickly.
This study is testing a special blood test called ROTEM to see how well it can predict bleeding problems in ICU patients with sepsis or severe trauma. It may help doctors give the right treatment faster.
This trial studies how well the body's natural clot-busting system works in people with serious infections or major injuries. It may help doctors find better ways to treat these conditions.
This study tests an investigational treatment called INTERCEPT Fibrinogen Complex (IFC) for people with severe bleeding after a traumatic injury. The treatment helps restore a key blood-clotting protein to try to stop the bleeding and improve survival.
Hear when a new Exanguination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.